| Identification | Back Directory | [Name]
D-Tyrosinamide, 4-chloro-L-phenylalanyl-D-cysteinyl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-lysyl-L-threonyl-L-cysteinyl-, cyclic (2→7)-disulfide | [CAS]
1801415-23-5 | [Synonyms]
JR11
Satoreotide
D-Tyrosinamide, 4-chloro-L-phenylalanyl-D-cysteinyl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-lysyl-L-threonyl-L-cysteinyl-, cyclic (2→7)-disulfide | [Molecular Formula]
C58H72ClN15O14S2 | [MOL File]
1801415-23-5.mol | [Molecular Weight]
1302.88 |
| Chemical Properties | Back Directory | [density ]
1.50±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
9.87±0.15(Predicted) | [color ]
White to off-white | [Sequence]
{p-Cl-Phe}-cyclo({d-Cys}-F-{d-4-amino-Phe(carbamoyl)}-KTC)-{d-Tyr}-NH2 |
| Hazard Information | Back Directory | [Uses]
Satoreotide (JR11) is a SSTR2 antagonist. Satoreotide is usually conjugated with radiolabeled chelators used in neuroendocrine tumor imaing[1]. | [IC 50]
SSTR2 | [References]
[1] Krebs S, et al. Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3047-3057. DOI:10.1007/s00259-020-04832-9 |
|
| Company Name: |
YantaiBio
|
| Telephone: |
13758194781; 13758194781 |
| Website: |
|
| Company Name: |
Fuan Bio
|
| Telephone: |
15002819872 |
| Website: |
fuanbio.com |
|